FDA feedback supports Company’s Phase 2 development strategy for Alzheimer’s disease asset; IND filing on track for H2 2021
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today announced that it has received feedback from the U.S. Food and Drug Administration ("FDA") supporting the Company’s development strategy to submit an initial new drug application ("IND") application for a Phase 2 study of Trappsol® Cyclo™ in the treatment of early Alzheimer’s disease, following a positive Type B interaction.
https://finance.yahoo.com/news/cyclo-therapeutics-proceed-ind-filing-132500068.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.